Cochin Minerals (513353)

Score breakdown: P/E: 2/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 1/1

Key Financials

Strengths

• ROCE of 23.32% indicates efficient use of capital in current operations.
• Dividend yield of 3.21% provides some cash return to shareholders.
• P/E of 13.25 and P/B of 1.51 are not expensive on the surface.
• Company is still profitable in the latest quarter with net profit of ₹3 Cr.
• Book value of ₹205.83 offers a tangible asset base for the current price.

Concerns

• Profit growth fell 40.64% while sales declined 4.54%, showing clear earnings deterioration.
• Piotroski F-Score of 3/9 indicates weak financial health and possible red flags.
• Latest quarterly net margin is only about 4.8% on ₹62 Cr sales, leaving a thin cushion.
• Promoter holding and debt/equity data are unavailable, making financial transparency insufficient.

AI Analysis

This business reminds me that a cheap multiple can be a trap when earnings are falling. Cochin Minerals sells at ₹310.90, a P/E of 13.25, but the 'E' in that ratio has just fallen by 40.64%. Sales are down 4.54% to ₹62 Cr in the latest quarter, and net profit is only ₹3 Cr — a thin margin. The Piotroski score of 3/9 tells me the financial foundation is deteriorating, not improving. I'd rather pay a fair price for a wonderful business than a bargain price for a business whose earnings quality is suspect. On the positive side, ROCE of 23.32% suggests the capital employed is generating reasonable returns, and a dividend yield of 3.21% gives some shareholder return. Book value of ₹205.83 means the stock trades at 1.51 times book — not unreasonable. But book value only matters if management can earn attractive returns on it consistently, and ROE of 9.49% is mediocre. The stock is at its 52-week high, which seems odd given the sharp profit decline; perhaps the market smells a cyclical recovery. I don't trust that. Without promoter holding data or a longer record of capital allocation, I cannot call this a compounder. This looks like a cyclical specialty chemical business, not a franchise with pricing power. I would wait for evidence of stabilised margins and, preferably, a lower price that provides a margin of safety. In Graham's language, it may be interesting, but it is not clearly safe.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer